Acute myeloid leukemia with mutated NPM1
Therapeutic area
Hematology
Rare disease
No
- Definition
- An acute myeloid leukemia with mutation of the nucleophosmin gene. It is usually associated with normal karyotype and frequently has myelomonocytic or monocytic features. It usually responds to induction therapy.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Acute myeloid leukemia with mutated NPM1
- Therapeutic area
- Hematology
- acute myeloid leukemia with mutated NPM1
- AML with mutated NPM1
- AML, Mutation of the Nucleophosmin Gene
- AML, NPM1 Mutation
- AML, NPM1 gene mutation
- AML, Nucleophosmin Gene Mutation
- NPMc+ AML
- acute myeloid leukaemia with cytoplasmic nucleophosmin
- acute myeloid leukemia with cytoplasmic nucleophosmin
- acute myeloid leukemia with mutated NPM1
- acute myeloid leukemia, NPM1 gene mutation
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0044923
- Parent condition
- MONDO:0018874
Related records
Broader conditions (32)
- Acute disease
- Acute leukemia
- Acute myeloid leukemia
- Bone cancer
- Bone disorder
- Bone marrow cancer
- Bone marrow disorder
- Bone marrow neoplasm
- Bone neoplasm
- Cancer
- Cancer or benign tumor
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
Trials (4)
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
- Oral Arsenic Trioxide for NPM1-mutated AML
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Drugs in development (1)
- Arsenic trioxide Phase 2